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Abstract We have studied the effect of a protein tyrosine
phosphatases (PTP) inhibitor on calcium-induced activation of
Xenopus laevis oocytes arrested at metaphase II. Ammonium
molybdate microinjection blocked pronucleus formation follow-
ing A23187 treatment while cortical granules still underwent
exocytosis. Pronuclei still occurred in ammonium molybdate-
injected oocytes following 6-DMAP addition. Changes that
usually occurred following A23187 exposure were inhibited in the
presence of ammonium molybdate in the oocyte : MAPK
dephosphorylation, p34cdc2 rephosphorylation and cyclin B2
and p39mos proteolysis. These results suggest that a PTP is
involved in the activation of the ubiquitin-dependent degradation
machinery.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Entry into M phase is due to the activation of MPF, a
kinase made up of two subunits: the catalytic subunit
p34cdc2 and the regulatory subunit cyclin [4,16]. Exit from
M phase is dependent on MPF inactivation. Cyclin is proteo-
lysed by the ubiquitin pathway [10,13] while p34cdc2 is dephos-
phorylated on T161 [19]. Ubiquitination of proteins requires a
20S multisubunit complex that has been termed the anaphase-
promoting complex (APC) which targets proteins for destruc-
tion by the 26S proteasome complex [34]. APC is believed to
be the target of a cell cycle-dependent regulation. Degradation
of cyclin B is stimulated in cell-free extracts prepared at in-
terphase by addition of puri¢ed MPF [6,19]. The MPF has
therefore been proposed to promote degradation of M phase
cyclins by a mechanism that remains almost completely un-
known [18,34].
In Xenopus, metaphase II arrest is due to a cytostatic factor
(CSF) [21]. Although CSF has not yet been puri¢ed, the prod-
uct of the protooncogene c-mos (p39mos) [28] and mitogen-
activated protein kinase (MAPK) [12] are thought to be in-
volved in CSF activity. MAPK could mediate the CSF activ-
ity of p39mos by preventing the cyclin degradation pathway
from being turned on and leading to the maintenance of a
high level of MPF activity in the cell [1]. This might be due to
the presence in the egg of an inhibitor acting either on APC
[1] or on ubiquitin-dependent proteolysis [36].
The interaction of the sperm with the egg membrane at
fertilization leads to egg activation. This is mediated by a
transient increase in intracellular calcium which induces cort-
ical granule exocytosis for fertilization membrane formation
as well as release from metaphase II arrest. Following this
increase in calcium, both CSF and MPF activities disappear
but MPF is inactivated before CSF [28,38]. Calcium/calmodu-
lin-dependent protein kinase II (CaMKII) has been shown to
act downstream of intracellular calcium elevation [20,25].
Although p39mos could be cleaved by the protease calpain
[30,37], its proteolysis is thought to occur by the ubiquitin
pathway [26]. MAPK is inactivated but this event is not re-
quired for CaMKII to turn on the cyclin degradation machi-
nery in CSF extracts [1]. This is consistent with the fact that
MAPK is inactivated after cyclin B proteolysis. It was sug-
gested that CaMKII could activate a phosphatase responsible
for the dephosphorylation of an inhibitor of APC [1].
The role of some protein phosphatases has already been
discussed as regulators of the APC. Cyclin B proteolysis has
been found to be inhibited by the microinjection of okadaic
acid (OA) into star¢sh oocytes [27]. It has recently been re-
ported in Xenopus egg extracts that proteolysis of cyclin B is
prevented by the use of OA, which induces an activity that
inhibits cyclin B ubiquitination [36]. Nevertheless, this activity
is still calcium-sensitive. Taken together, these results indicate
a role for protein phosphatases in the metaphase-anaphase
transition.
However, less is known about the role of protein tyrosine
phosphatases (PTP) in the metaphase-anaphase transition. We
have addressed the question of involvement of these PTP in
the activation of Xenopus metaphase II-arrested oocytes, by
using ammonium molybdate, a PTP inhibitor [15,22]. We re-
port that inhibition of PTP blocks A23187-induced pronu-
cleus formation. At the molecular level, ammonium molyb-
date inhibited not only the dephosphorylation of MAPK but
also the proteolysis of cyclin B and p39mos. This inhibitory
e¡ect may be due to a PTP implicated in the regulation of the
APC.
2. Materials and methods
2.1. Handling of oocytes and gametes
Adult Xenopus laevis females were purchased from C.R.B.M.
(C.N.R.S., Montpellier France). Full-grown stage VI oocytes [5]
were obtained as previously described [9] and used in ND96 medium
(96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM
HEPES, pH 7.5/NaOH). Progesterone was used overnight at 10 WM
to obtain metaphase II-arrested oocytes. A23187 (Boehringer Mann-
heim) was used at 10 WM from a stock solution (100 mM) prepared in
DMSO. 6-DMAP (Sigma) was diluted in ND96, and used at 12 mM.
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This concentration was chosen since it was reported to induce egg
activation within 30 min [39]. All experiments were performed at
20‡C and at least in triplicate.
2.2. Microinjections
The PTP inhibitor ammonium molybdate [15,22] (Sigma) was mi-
croinjected into in vitro matured oocytes, by the use of a positive
displacement digital micropipette (Nichiryo) in a calcium-limited me-
dium (CaLM: 120 mM NaCl, 7.5 mM KCl, 22.5 mM HEPES, 400
WM EDTA, 500 WM MgSO4, 150 WM CaCl2, pH 7.4), in order to
prevent activation due to pricking [39]. After injection of ammonium
molybdate (1.6 mM ¢nal), the oocytes were allowed to heal for 15 min
in this medium, and then incubated for 45 min in ND96 for the
ammonium molybdate to di¡use throughout the oocytes, before treat-
ment with A23187 or 6-DMAP.
2.3. Cytological analysis
Oocytes were ¢xed overnight in Smith’s ¢xative, sectioned and
stained with nuclear red to detect nuclei and chromosomes, and
with picroindigo carmine which reveals cytoplasmic structures [9].
In order to detect cortical granule exocytosis, oocytes were ¢xed in
ND96 medium pH 7.5 containing 2.5% glutaraldehyde, after cutting
into two parts to improve ¢xation. They were then dehydrated in a
graded series of acetone, embedded in EMbed 812 and sectioned with
a Reichert OmU2 ultramicrotome (Reichert, Vienna, Austria). Sec-
tions (1 Wm thick) were stained with a 0.1% toluidine blue solution.
2.4. Electrophoresis and Western blotting
Oocytes (20 per batch) were homogenized in homogenization bu¡er
[2] and centrifuged for 10 min at 10 000Ug (4‡C) to eliminate yolk
platelets. Supernatants were then incubated at 4‡C for 30 min, under
constant rotation with 10 Wl p9CKShs1-Sepharose beads. After a brief
centrifugation, one volume of 2ULaemmli sample bu¡er was added
to one volume of supernatant for p39mos and MAPK analysis. Beads
were washed three times with ice-cold bead bu¡er [2] and treated with
2ULaemmli sample bu¡er for detection of p34cdc2 and cyclin B2.
Oocyte proteins were denatured by heating the mixture (100‡C,
5 min) and then separated by 10% SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE). In the particular case of MAPK immunode-
tection, proteins were resolved by 15% SDS-PAGE (prepared from a
stock solution containing 29.82% acrylamide/0.18% bisacrylamide).
Such gels allowed a good discrimination between active and inactive
MAPK [3]. Separated proteins were subjected to Western blot analysis
as previously reported [9]. p34cdc2 was detected using the monoclonal
antibody A17 [11] (1/1000 in TBS). MAPK was detected using the
anti-Erk2 monoclonal antibody D-2 (Santa Cruz Biotechnology, Hei-
delberg, Germany) (1/2500 in TBS). Cyclin B2 was detected using the
monoclonal antibody X121 diluted at 1/1000 in TBS. p39mos was
detected using the rabbit polyclonal antibody C-237 (Santa Cruz Bio-
technology, Heidelberg, Germany), 1/1000 in TBS.
3. Results and discussion
3.1. Cytological analysis of ammonium molybdate-injected
oocytes
The results of this analysis are summarized in Fig. 1. A
pronucleus was observed in 100% of the in vitro matured
oocytes that had been exposed to calcium ionophore
A23187 (10 WM) or 6-DMAP (12 mM) for 60 min. Ammo-
nium molybdate microinjection itself did not trigger activation
of the oocytes. When treated by calcium ionophore, 14% of
oocytes microinjected (n = 14) showed pronucleus formation.
Ammonium molybdate did not block pronucleus formation
induced by 6-DMAP, since pronuclei were found in 70% of
the oocytes (n = 10).
This result showing that ammonium molybdate inhibits cal-
cium-induced pronucleus formation suggests that PTP play an
important role in the cascade of events leading to pronucleus
formation. This con¢rms a recent report indicating that inhi-
bition of PTP with sodium orthovanadate leads to disruption
of sperm-induced Xenopus egg activation [31], even if these
authors observed only cortical reaction without pronucleus
analysis.
One might argue that the lack of pronucleus might be due
to a toxic e¡ect of the drug. However, this does not seem to
be the case since 6-DMAP, a kinase inhibitor able to activate
Xenopus eggs in the absence of calcium changes [39], induced
pronucleus formation in these injected oocytes.
Another explanation might be that the calcium increase
could not occur in these injected oocytes. Since cortical gran-
ule exocytosis is a reliable event associated with calcium
changes in the egg, we analyzed the cortical granule content
of in vitro matured oocytes. In control oocytes, cortical gran-
ules were located under the plasma membrane (Fig. 2A), while
these granules underwent exocytosis after A23187 treatment
(Fig. 2B). Ammonium molybdate injection itself did not trig-
ger cortical granule exocytosis (Fig. 2C). The presence of the
PTP inhibitor did not block exocytosis induced by the calcium
ionophore (Fig. 2D). The vitelline envelope was not present
on the sections because oocytes were cut into two halves to
aid ¢xation. The fact that cortical granule exocytosis still oc-
curred in oocytes injected with ammonium molybdate follow-
ing A23187 addition demonstrated that the PTP inhibitor did
not prevent the increase in intracellular calcium.
3.2. Analysis of MPF and CSF in ammonium molybdate-
injected oocytes
First, phosphorylation states of p34cdc2 and MAPK were
analyzed. p34cdc2 may appear as two forms on Western blots:
the slow migrating band is inactive and phosphorylated on
three residues (Thr-14, Tyr-15 and Thr-161), the fast migrat-
ing band is either unphosphorylated and inactive or mono-
phosphorylated (Thr-161) and active [32]. Two forms of
MAPK may also be detected: an active tyrosine phosphoryl-
ated form and an unphosphorylated faster migrating inactive
form [24].
Immature oocytes contain two forms of p34cdc2 and the
dephosphorylated form of MAPK whereas matured oocytes
contain only the fast migrating band for p34cdc2 and the slow
Fig. 1. Pronucleus formation after treatment with A23187 or
6-DMAP of metaphase II-arrested oocytes previously injected with
ammonium molybdate. Oocytes were injected or not with ammo-
nium molybdate and 1 h later they were incubated for 1 h in con-
trol or test solutions. Results are expressed as percentage of oocytes
showing a pronucleus on the histological sections. No pronuclei
were found in matured oocytes, even 2 h after the injection of am-
monium molybdate. Matured oocytes showed a pronucleus in all
cases when analyzed after 1 h of A23187 or 6-DMAP exposure. In
the presence of the PTP inhibitor, only 14% (n = 14) of the A23187-
treated oocytes showed a pronucleus whereas such a structure was
found in 70% (n = 10) of the 6-DMAP-treated oocytes.
FEBS 22434 25-8-99
J.-F. Bodart et al./FEBS Letters 457 (1999) 175^178176
migrating band for MAPK (Fig. 3). In metaphase II-arrested
oocytes previously injected with ammonium molybdate, calci-
um ionophore failed to induce changes in the immunodetec-
tion pro¢les of p34cdc2 and MAPK (Fig. 3).
Ammonium molybdate inhibited calcium-induced dephos-
phorylation of MAPK, providing e⁄ciency of its inhibitory
action. Indeed, it is well-known that tyrosine dephosphoryla-
tion of MAPK is a key event for its inactivation [7]. MAPK
phosphatases have been found in Xenopus egg extracts: an
uncharacterized 47 kDa PTP was puri¢ed from the cytosolic
fraction of Xenopus eggs [29], and XCL100, close to the
mouse homologue CL100, has been cloned in Xenopus em-
bryos and shown to inactivate MAPK [17]. In metaphase II-
arrested extracts of Xenopus eggs, ectopic overexpression of a
C-terminally truncated form of CL100 results in premature
inactivation of MAPK and exit from metaphase arrest [23].
The role of MAPK in the metaphase II arrest has recently
been discussed. MAPK has been shown to prevent the cyclin
B degradation rather than to inhibit it [1]. Indeed, in meta-
phase II-arrested oocytes extracts, CaMKII is able to release
metaphase block, and to trigger cyclin degradation without
inactivation of MAPK. This is consistent with the fact that
MAPK inactivation does not occur earlier than 20^30 min
after fertilization, which is well after cyclin degradation [1].
So we focused on the proteolysis of the components of
MPF and CSF. When calcium ionophore A23187 was applied
on matured oocytes, cyclin B2 was degraded in the ¢rst min-
utes and was not detected on the Western blots performed
after 20 min. The kinase p39mos was not detected on the West-
ern blots performed after a 60 min A23187 exposure (Fig. 3).
PTP inhibition by itself did not a¡ect the stability of the two
proteins (Fig. 3). In homogenates of oocytes exposed for
20 min to 10 WM A23187 after ammonium molybdate injec-
tion, cyclin B2 and p39mos were still detected (Fig. 3).
Fig. 2. Sections of matured oocytes showing cortical granule content following ammonium molybdate microinjection and treatment with
A23187. In vitro matured oocytes were injected or not with ammonium molybdate and 1 h later, they were treated or not with A23187 for 20
min. Cortical granules (CG) appeared located under the plasma membrane in control metaphase II-arrested oocytes (A) as well as in oocytes
injected with ammonium molybdate (C). A23187 induced CG exocytosis in matured oocytes (B) even in the presence of ammonium molybdate
(D) (U1000). The vitelline envelope is not observed on the sections due to its loss following the cutting of the oocytes into two halves to im-
prove ¢xation.
Fig. 3. Western blot analysis of p34cdc2, p39mos, MAPK and cyclin
B2 in metaphase II-arrested oocytes microinjected with ammonium
molybdate and treated with A23187. Metaphase II-arrested oocytes
were injected or not with ammonium molybdate and 1 h later they
were treated or not with A23187. Analyses were performed after
20 min for cyclin B2 and after 60 min for the other proteins. In ho-
mogenates from immature oocytes (I), we observed two forms of
p34cdc2 the absence of p39mos, the dephosphorylated form of MAPK
and two cyclin B2 isoforms. In matured oocytes (M), we found the
fast migrating form of p34cdc2, p39mos which was synthesized in re-
sponse to progesterone, the phosphorylated active form of MAPK
and the phosphorylated form of cyclin B2. Microinjection of the
PTP inhibitor alone did not modify these pro¢les. Treatment with
10 WM A23187 induced rephosphorylation of p34cdc2, degradation
of p39mos, dephosphorylation of MAPK and degradation of cyclin
B2. These changes failed to occur when A23187 was applied on oo-
cytes previously microinjected with the PTP inhibitor.
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Why are these oocytes unable to carry out the proteolysis of
cyclin B2 and P39mos when PTP are inhibited? In the budding
yeast Saccharomyces cerevisiae, Cdc14p, a dual speci¢city
PTP, is required for cell cycle progression [33]. Cdc14p mu-
tants, arrested in late mitosis, expressed a phenotype similar
to that of cells expressing a non-degradable form of mitotic
cyclins [8]. It has been proposed that Cdc14p induces degra-
dation of mitotic cyclins through dephosphorylation of Cdh1/
Hct1, the function of which is to activate APC [14,35]. Cdh1/
Hct1 belongs to a family of proteins containing seven WD-40
repeats in their C-termini, involved in the regulation of the
ubiquitin-proteasome pathway in both yeast and eukaryotes.
A similar explanation might be proposed in Xenopus oocytes
in which a PTP might be located downstream of calcium and
CaMKII and upstream of APC.
In conclusion, our study shows that the calcium ionophore
A23187 cannot induce pronucleus formation when PTP are
inhibited. Since this e¡ect is mediated not only by the inhib-
ition of MAPK dephosphorylation but also by the inhibition
of cyclin B2 and p39mos proteolysis, we suggest that a PTP
sensitive to ammonium molybdate is involved in APC regu-
lation. The identi¢cation of this enzyme could be of great
interest for the understanding of cell cycle regulation.
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